ASK1 Inhibitor in Chronic Kidney Disease Therapy: From Bench to Bedside

Kidney360. 2022 Jul 28;3(7):1128-1131. doi: 10.34067/KID.0002562022.

Authors

Lu Wen^{1

2}, Qingqing Wei¹

Affiliations

¹ Department of Cellular Biology and Anatomy, Medical College of Georgia, Augusta University, Augusta, Georgia.
² Hunan Key Laboratory of Kidney Disease and Blood Purification, Department of Nephrology, The Second Xiangya Hospital of Central South University, Changsha, People's Republic of China.

No abstract available

Keywords: ACEi; ASK1; CKD; chronic kidney disease; fibrosis; selonsertib.

Publication types

Editorial
Research Support, N.I.H., Extramural
Comment

MeSH terms

Humans
Protein Kinase Inhibitors* / pharmacology
Renal Insufficiency, Chronic* / drug therapy

Substances

Protein Kinase Inhibitors

Grants and funding

R01 DK126763/DK/NIDDK NIH HHS/United States